SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules.
Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.
Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their R&D goals
Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.
From route scouting for complex APIs and method development, to large-scale cGMP manufacturing, we are your dedicated partner for accelerating chemical process development.
Syngene has built credibility in chemical product development through experienced scientists, cutting-edge infrastructure, robust quality systems, and a proven track record. Noteworthy achievements include developing the world’s first drug for a rare paediatric disease and delivering significant cost savings for clients.
Commitment to innovation, compliance, and sustainability—plus being a publicly listed company—solidifies Syngene’s position as a trusted global CDMO.
Syngene’s workforce includes process chemists, engineers, and analytical scientists with expertise across synthetic organic chemistry, process chemistry, analytical chemistry, process safety, and engineering. Supported by supply chain, QC, and QA experts, we provide a complete ecosystem for reliable chemical development.
Key Value Drivers: